Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and the University of Wisconsin (UW) School ...
Dr Constantinos Patinios, a researcher at the EMBL Partnership Institute at Vilnius University Life Sciences Center (VU LSC), ...
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
Seek Labs, a private TechBio company building a programmable disease response platform to detect, protect, and counter disease threats, has been awarded $2 million from the U.S. D ...
CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.
Oral diseases are a significant global health issue, affecting both quality of life and overall systemic health. Animal ...
Today’s Forbes Daily also covers Anthropic’s hot streak, a junk bond master, Les Wexner’s upcoming Epstein deposition, cutting edge bobsled engineering and more.
5d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Agriculture faces unprecedented challenges from environmental pressures and increasing demand for food production. As global ...
CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with ...
Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results